Amgen Inc. (AMGN)

Amgen Inc.'s Q·Score is 6.9/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. High-quality business with 91% return on equity and 23% profit margins. Key area to monitor: high leverage at 4.9× debt-to-equity. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for AMGN is $388.48, based on ratings from 29 Wall Street analysts. This is 11.6% below the current price of $439.33. Price targets are forward-looking estimates and not guarantees of future performance.

Amgen Inc. (AMGN) scores in line with sector averages on valuation metrics. Its forward P/E ratio stands at 18.0×. The consensus analyst price target of $388.48 is 12% below the current price.

Amgen Inc.'s next earnings report is expected on approximately November 3, 2026.

Amgen Inc. has a net profit margin of 23.0%, which is considered high and reflects strong pricing power. Its gross margin stands at 71.9%, indicating a high-margin business model.

Amgen Inc. currently offers a dividend yield of 2.29%, which is above the typical market average dividend yield. Dividend yields can change based on price movements and company payout decisions.

Amgen Inc. is reporting modest revenue growth of 9.5%. Earnings are also growing at 64.9%, indicating improving profitability.

Amgen Inc. has a debt-to-equity ratio of 4.90×, reflecting a high debt-to-equity ratio, which increases financial risk especially in rising rate environments. Its current ratio is 1.37×, suggesting it should be monitored for near-term liquidity.